Lupin Pharmaceuticals Inc. recalls Liraglutide Injection
- Published
- 27 May 2026
- Units affected
- 217,621 pen injectors
- Agency
- FDA
- Country
- United States
The hazard
Presence of particulate matter: a white thread-like structure in the cartridge
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur 441108, INDIA, a) 2 Pens- NDC 70748-346-02; b) 3 Pens - NDC 70748-346-03.
- Brand / company
- Lupin Pharmaceuticals Inc.
- Codes / lots
- Lots: a) WB00097, WB00094, WB00088, Expires: Jul. 2027; WB00103, Expires: Oct. 2027; WC00016, Expires: Dec. 2027; b) WB00098, WB00092, WB00093, Expires: Jul. 2027; WB00104, WB00106, WB00105, Expires: Oct. 2027.
- Distribution
- Nationwide within U.S
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 27 May 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.